InvestorsHub Logo
Followers 12
Posts 1124
Boards Moderated 0
Alias Born 12/22/2017

Re: Lakersrback post# 26223

Wednesday, 04/21/2021 10:52:19 AM

Wednesday, April 21, 2021 10:52:19 AM

Post# of 27409
Well said and I agree with your comments.

Ironically in the end the HemoDefend (HD)product line which has been proven under Darpa and Army contracts would serve a HUGE global market seeking a safer and larger universal blood supply. Maybe easier to get through the FDA.

Maybe not a revenue producing product until 2023? At $100 million in revenues the first full year with 70-80% gross margins in the new automated NJ manufacturing facility HD could be the sleeper in CTSO product portfolio.

Made at a future overseas contract facility would be very strong after tax cash generator. HD division would certainly be attractive to Hemonetics as a distribution partner and/or acquisition.
https://haemonetics.gcs-web.com/static-files/b56e06b2-ffa4-4a52-ab7b-9d94322139e8
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News